What is it about?
Recently, carbapenems have shown promising results for treatment of drug resistant Tuberculosis. Anticipating the emergence of carbapenem resistant TB in future, we have discovered molecular mechanism of this resistance.
Featured Image
Why is it important?
We have discovered a novel marker that is associated with carbapenem resistance in TB. Our discovery can be used for developed of diagnostic tools for detection of carbapenem resistant TB in future.
Perspectives
Our research work on mechanism of carbapenem resistance in TB has discovered a new carbapenem target in Mycobacterium tuberculosis. This research will lead to the development of new inhibitors in future to treat drug-resistant TB. We have discovered a new class of enzyme that shows a beta-lactamase activity. Genetic and Structure-Function studies will reveal more about the function of this new enzyme in future. Dr. Gyanu's vision on understanding the carbapenem resistance in TB have led to the discovery of new carbapenem resistance factor, CrfA. I contributed to validation of CrfA in Mycobacterium tuberculosis through microbiological, proteomic and biochemical approaches. I also discovered the carbapenem binding and ß-lactamase activity of CrfA and screened several ß-lactam antibiotics that inhibit this new enzyme through several biophysical and drug screening approaches.
Dr Pankaj Kumar
Jamia Hamdard
Read the Original
This page is a summary of: Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals,
DOI: 10.1128/aac.02234-16.
You can read the full text:
Contributors
The following have contributed to this page
